You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):AK127聯合AK104治療晚期或轉移性實體瘤臨牀研究完成首例患者給藥
格隆匯 10-22 06:17

格隆匯10月22日丨康方生物-B(09926.HK)發佈公吿,公司自主研發的TIGIT單克隆抗體(研發代號:AK127),聯合公司全球首創的凱得寧(PD-1/CTLA-4雙特異性抗體,研發代號:AK104)治療晚期或轉移性實體瘤的I期臨牀研究在澳大利亞完成首例患者給藥。

在TIGIT單抗聯合PD-1單抗療法展現良好的臨牀前及臨牀療效的基礎上,AK127聯合凱得寧治療實體瘤患者,有望取得更顯著的抗腫瘤活性,更進一步提升聯合療法的潛力和前景,加強和豐富公司腫瘤免疫治療的多靶點組合。

公司通過打造豐富的癌症治療產品管線,積極開展和各類極具潛力的免疫靶點的聯合療法,深度挖掘以PD-1抗體為基石的雙特異性抗體的商業價值。目前,凱得寧聯合CD47單抗(研發代號:AK117)、VEGFR-2單抗(研發代號:AK109)、CD73單抗(研發代號:AK119)及PD-1/VEGF(研發代號:AK112)聯合AK117等臨牀研究均已成功開展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account